Breaking Barriers: Dr. Mitzi Joi Williams on Pioneering MS Clinical Trial for the Black Community

In a groundbreaking interview with Dr. Mitzi Joi Williams, one of the clinical leads and heads of the steering committee for, CHIMES (the first-ever multiple sclerosis (MS) clinical trial developed by Genentech exclusively focused on the Black and Hispanic community in the United States) we delve into the significance of the trial, the existing gaps in MS research, and the innovative strategies employed to make clinical trials more inclusive. Understanding the Significance Recent data has debunked historical misconceptions about MS not affecting Black individuals. Over the past decade, research has shown that the incidence of MS is highest among Black people in the U.S., with some studies suggesting up to a 47% higher risk in Black women.  The trial seeks to address the lack of research in this area, aiming to unravel the baseline characteristics and factors contributing to the disproportionate impact of MS on Black and Hispanic populations. “This is a really important trial because, over the past decade or so, we’ve been learning more about MS in the Black community,” Dr, Williams shares.  Addressing Existing Gaps in Research According to studies, Black and brown communities with MS have worse outcomes, such as faster disability progression, more brain damage...